Lōkahi Therapeutics signs first external client for asset search platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
September 23, 2026 4:30 PM EDTInnovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development
RUTHERFORD, N.J. & LA JOLLA, Calif. & LOS ANGELES--(BUSINESS WIRE)-- Lkahi Therapeutics Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblastoma (GBM) and other brain tumors, has engaged two ai² PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and... More



